49.82USD+5.33%Mkt Cap: 7.24B USDP/E: —Last update: 2026-05-26
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-spari…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap7.24B USD
Enterprise Value5.22B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-766.63M USD
Revenue/Share—
Last Price49.82 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees507
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.39
PEG—
EV/EBITDA-4.87
EV/Revenue—
P/S—
P/B2.28
EPS (TTM)-6.89
EPS (Forward)-7.42
52W Range
29.0858% of range65.00
52W High65.00 USD
52W Low29.08 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.55%
ROA-25.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-655.58M USD
CapEx (TTM)56.97M USD
FCF Margin—
FCF Yield-6.07%
Net Debt-1.62B USD
Net Debt/EBITDA1.51
Balance Sheet
Debt/Equity0.04
Current Ratio7.49
Quick Ratio7.18
Book Value/Sh20.76 USD
Cash/Share12.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)109.00 USD
Target Range67.00 USD – 163.00 USD
# Analysts9
Ownership
Shares Out.144.40M
Float131.96M
Insiders0.53%
Institutions114.64%
Short Interest
Short Ratio11.8d
Short % Float9.85%
Short % Out.9.80%
Shares Short14.14M
Short (prev mo.)13.69M
Technical
SMA 5056.62 (-12.0%)
SMA 20047.39 (+5.1%)
Beta1.30
S&P 52W Chg28.31%
Avg Vol (30d)1.47M
Avg Vol (10d)1.69M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—